Effect of confounding factors on a phospho-flow assay of ribosomal S6 protein for therapeutic drug monitoring of the mTOR-inhibitor everolimus in heart transplanted patients.
Biomarkers
; 22(1): 86-92, 2017 Feb.
Article
em En
| MEDLINE
| ID: mdl-27448205
ABSTRACT
CONTEXT Several assays of monitoring immune cell function have been developed to enhance therapeutic drug monitoring. OBJECTIVE:
An in vitro-validated whole-blood assay of phosphorylated ribosomal protein S6 (pS6RP) was evaluated for confounders to monitor the mTOR-inhibitor everolimus (ERL). MATERIALS ANDMETHODS:
Whole blood samples from 87 heart transplant recipients were analyzed for pS6RP-expression in CD3-positive T-cells by phospho-flow analysis.RESULTS:
ERL blood concentration, laboratory parameters, co-medications, demographic and clinical data were reviewed.CONCLUSION:
Evaluating the pS6RP-assay revealed that pS6RP is influenced by cyclosporine A (CsA) blood concentration, duration of ERL treatment, co-medication with thiazide diuretics and different metabolic parameters.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Transplante de Coração
/
Proteína S6 Ribossômica
/
Everolimo
Limite:
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article